Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction

• Published in: European urology focus 2022-05, Vol.8 (3), p.794-802
• Main Authors: von Büren, Moritz, Rodler, Severin, Wiesenhütter, Isabell, Schröder, Florian, Buchner, Alexander, Stief, Christian, Gratzke, Christian, Wülfing, Christian, von Büren, Johannes
• Format: Article
• Language: English
• Subjects: Carbolines - therapeutic use; Digital healthcare; Erectile dysfunction; Erectile Dysfunction - chemically induced; Erectile Dysfunction - drug therapy; Humans; Male; Online prescription platform; Patient Preference; Phosphodiesterase 5 Inhibitors - therapeutic use; Phosphodiesterase-5 inhibitor; Piperazines - therapeutic use; Purines - therapeutic use; Retrospective Studies; Sildenafil Citrate - therapeutic use; Sulfones - therapeutic use; Tadalafil - therapeutic use
• ISSN: 2405-4569; 2405-4569
• DOI: 10.1016/j.euf.2021.04.019

Erectile dysfunction (ED) is a major care problem worldwide. Tadalafil and sildenafil are the two most common phosphodiesterase-5 inhibitors (PDE5is) used to treat ED. This study aimed to evaluate patient data of a large online prescription platform (OPP), specifically analyzing preference for tadalafil over sildenafil. Data from a prospectively collected German OPP were retrospectively analyzed. This dataset included patients with a history of taking one or both substances (n = 26 821). ED patient baseline characteristics were derived from medical questionnaires for PDE5i prescriptions between May 2019 and May 2020. Order behavior was analyzed in patients who ordered both substances over time. We applied Kruskal-Wallis tests, χ² tests, and fisher’s exact tests for statistical analysis. Baseline characteristics were comparable for both PDE5is in patients with a median age of 49 yr (sildenafil [interquartile range {IQR} 38–57]; tadalafil [IQR 39–56]), a median body mass index (BMI) of 26 kg/m² (sildenafil [IQR 24.54–29.03]; tadalafil [IQR 24.49–28.69]), ED onset time of >12 mo (sildenafil [87%]; tadalafil [88%]), and the presence of morning erections (sildenafil [62%]; tadalafil [61%]). Tadalafil prescriptions increased significantly from 30% (first order) to 80% (last order) in patients who had already tested both drugs. Patients with age ≤40 yr, BMI ≤25 kg/m², and sustained morning erections preferred tadalafil to sildenafil. Using database information from an OPP, preference for tadalafil was shown for patients who had tested both PDE5is. This preference was particularly pronounced in patients with age ≤40 yr, BMI ≤25 kg/m², and sustained morning erections. A well-managed OPP can be used for research on more complex health services. Analysis of large online prescription platforms provide the benefit of identifying young treatment-naïve patients with early-stage disease, which is highlighted by the fact that about two-thirds of our patients analyzed still maintained spontaneous morning erections. Patients who had tested tadalafil once developed preference for this drug. An analysis of large online prescription platforms provides the benefit of identifying young, treatment-naïve, early-stage-disease patients. About two-thirds of our patients analyzed still maintained spontaneous morning erections. Patients who had tested tadalafil once developed a preference for this drug.